ClinicalTrials.gg
Not yet recruitingNCT07849348Updated Sep 30, 2026

Study on the Efficacy and Safety of Initial Combination of Finerenone and Semaglutide in Non-Diabetic Adult Patients With Obesity Complicated by Chronic Kidney Disease With Albuminuria

An interventional study of Finerenone and Finerenone Placebo in Obesity; Chronic Kidney Disease; Albuminuria, sponsored by Peking University People's Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Peking University People's Hospital · Not applicable, Interventional, and Treatment

How we know · 6 judgments

Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
266
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate whether starting finerenone together with semaglutide provides an additional reduction in urinary albumin-to-creatinine ratio compared with semaglutide plus matching placebo in adults in China with obesity, albuminuric chronic kidney disease, and without diabetes. Approximately 266 participants will be randomized in a 1:1 ratio. The treatment period will last 24 weeks, followed by a 4-week off-treatment follow-up period.

Read the detailed description

Eligible participants will be randomized 1:1 to semaglutide plus finerenone or semaglutide plus matching finerenone placebo. Randomization will be stratified by baseline UACR category and BMI category. Semaglutide will be initiated at 0.25 mg once weekly and escalated every 4 weeks to a maximum of 2.4 mg once weekly as tolerated. Finerenone or matching placebo will start at 10 mg or 20 mg once daily according to baseline eGFR, with protocol-defined dose adjustment based on serum potassium and eGFR. The double-blind treatment period is 24 weeks, followed by 4 weeks off treatment. The primary objective is to compare change from baseline in UACR at Week 24. Secondary and other outcomes assess albuminuria response, kidney function, body size, blood pressure, inflammation, metabolic markers, and safety.

02

Conditions studied

  • Obesity; Chronic Kidney Disease; Albuminuria

Keywords

  • Obesity-related chronic kidney disease; Non-diabetic; Albuminuria; Finerenone; Semaglutide; Mineralocorticoid receptor antagonist; GLP-1 receptor agonist; UACR
03

In context

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

This study's planned enrollment of 266 is above the median of 67 across 9,043 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Peking University People's Hospital is the lead sponsor of 611 studies on the registry; 248 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Age >=18 years at the time of signing the form, without gender restriction;
  • 2. Meet one of the following definitions of excess adiposity at screening:

    1. >=28 kg/m\^2 and waist-to-height ratio >=0.5;
    2. Direct body fat measurement shows significantly elevated body fat percentage (>=25% for adult males and >=30% for adult females), which can be measured by bioelectrical impedance analysis (BIA), dual-energy X-ray absorptiometry (DEXA), or other methods;
  • 3. Clinically diagnosed with chronic kidney disease (CKD), and meet all of the following:

    1. At least 2 consecutive documented UACR values >30 mg/g within 12 weeks prior to screening; UACR ranges from 100 to 3500 mg/g (11.4-395.9 mg/mmol) at screening;
    2. >=25 mL/min/1.73 m\^2 at screening (calculated using the CKD-EPI equation);
  • 4. Stable renal function at screening, defined as a change in eGFR of less than 30% within 12 weeks prior to screening;
  • 5. Voluntarily sign the informed consent form and be willing to strictly comply with all requirements and restrictions specified in the informed consent form and this protocol throughout the study period.

Exclusion criteria

Exclusion Criteria:

  • 1. Known allergy to the study drug (active ingredients or ) or similar drugs.
  • 2. A previous diagnosis of type 1 diabetes mellitus [including latent diabetes in adults (LADA)], type 2 diabetes mellitus, or other types of diabetes mellitus; or >= 6.5% or fasting blood glucose >= 7.0 mmol/L at screening.
  • 3. Serum potassium > 5 mmol/L at screening.
  • 4. Patients with chronic kidney disease (CKD) requiring hormonal or therapy within 6 months prior to screening.
  • 5. Mean blood pressure > 160/100 mmHg or mean systolic blood pressure \< 90 mmHg at screening.
  • 6. History of renal transplantation, or acute kidney injury requiring dialysis within 24 weeks prior to the screening visit.
  • 7. Occurrence of any acute cardiovascular or cerebrovascular events within 12 weeks prior to screening, including decompensated heart failure, myocardial infarction, stroke, , pulmonary embolism, elective percutaneous coronary intervention, or coronary artery bypass grafting.
  • 8. Prior treatment with mineralocorticoid receptor antagonists (MRAs) (e.g., finerenone, eplerenone, esaxerenone, spironolactone, canrenone) or renin inhibitors within 8 weeks prior to screening.
  • 9. Prior treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs) within 8 weeks prior to screening.
  • 10. Ongoing or planned treatment with potassium supplements, potassium-sparing diuretics (e.g., amiloride, triamterene), or potassium-binding agents within 8 weeks prior to screening.
  • 11. Use of traditional Chinese medicines that may affect urinary protein excretion.
  • 12. Receiving continuous treatment with strong inhibitors (e.g., itraconazole, clarithromycin, ketoconazole, ritonavir, nelfinavir, cobicistat, telithromycin, nefazodone), strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, phenobarbital, St. John's wort), or moderate CYP3A4 inducers (e.g., efavirenz) that cannot be discontinued, with no drug for at least 7 days prior to randomization.
  • 13. Hepatic insufficiency ( Class C).
  • 14. Addison's disease.
  • 15. Symptomatic heart failure with reduced that requires MRA administration as standard therapy.
  • 16. Uncontrolled thyroid disease at screening (defined as TSH > 6.0 mIU/L or \< 0.4 mIU/L), personal or family history of medullary thyroid carcinoma, or diagnosis of multiple endocrine neoplasia type 2 syndrome.
  • 17. History of acute pancreatitis within 24 weeks prior to screening, or current chronic pancreatitis.
  • 18. Participation in any other interventional clinical trial or use of any product within 12 weeks prior to randomization.
  • 19. History of alcohol or substance abuse.
  • 20. Females of who are pregnant, breastfeeding, intend to become pregnant during the study period, or fail to adopt effective measures.
  • 21. Any other medical conditions that, in the investigator's judgment, may interfere with the efficacy or safety assessment of the study and make the subject inappropriate for study participation.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
266 participants (estimated)

Study arms

  • Experimental
    Finerenone combined with semaglutide injection

    Drug: Finerenone · Drug: Semaglutide

  • Placebo comparator
    Finerenone placebo combined with semaglutide injection for intervention

    Drug: Finerenone Placebo · Drug: Semaglutide

Interventions

  • Oral finerenone once daily for 24 weeks. Starting dose is 10 mg for eGFR 25 to \<60 mL/min/1.73 m2 and 20 mg for eGFR \>=60 mL/min/1.73 m2, with protocol-defined adjustment based on serum potassium and eGFR.

  • DrugFinerenone Placebo

    Oral matching placebo once daily for 24 weeks, with tablet number and protocol-defined adjustment procedures matched to finerenone.

  • Subcutaneous semaglutide once weekly: 0.25 mg for Weeks 1-4, 0.5 mg for Weeks 5-8, 1.0 mg for Weeks 9-12, 1.7 mg for Weeks 13-16, and 2.4 mg from Week 17 through Week 24, or the maximum tolerated dose.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Urinary Albumin-to-Creatinine Ratio (UACR) at Week 24

    Time frame: Baseline to Week 24

Secondary outcomes

  1. Proportion of Participants With UACR <30 mg/g at Week 24

    Percentage of participants meeting the protocol-defined albuminuria remission threshold.

    Time frame: Baseline to Week 24

  2. Proportion of Participants Achieving a ≥30%, ≥40%, or ≥50% Reduction in UACR from Baseline

    Percentage of participants with a reduction in UACR of at least 30%, 40%, or 50% from baseline.

    Time frame: Baseline to Week 24

  3. Proportion of Participants With Regression of Albuminuria Category

    Regression is defined as a change from UACR \>=300 mg/g to 30-299 mg/g, or from UACR 30-299 mg/g to \<30 mg/g.

    Time frame: Baseline to Week 24

  4. Change From Baseline in Creatinine-based Estimated Glomerular Filtration Rate (Cr-eGFR)

    Cr-eGFR will be calculated using the CKD-EPI equation.

    Time frame: Baseline to Week 24

  5. Change From Baseline in Cystatin C-based Estimated Glomerular Filtration Rate (Cys-C-eGFR)

    Change in Cys-C-eGFR from baseline.

    Time frame: Baseline to Week 24

  6. Estimated Glomerular Filtration Rate Slope Through Week 24

    Rate of change in eGFR over the 24-week treatment period.

    Time frame: Baseline through Week 24

  7. Change From Baseline in Body Weight

    Time frame: Baseline to Week 24

  8. Change From Baseline in Waist Circumference

    Time frame: Baseline to Week 24

  9. Change From Baseline in Body Mass Index (BMI)

    Time frame: Baseline to Week 24

  10. Change From Baseline in Waist-to-Height Ratio

    Time frame: Baseline to Week 24

  11. Change From Baseline in High-sensitivity C-reactive Protein (hsCRP)

    Time frame: Baseline to Week 24

  12. Change From Baseline in Systolic Blood Pressure

    Time frame: Baseline to Week 24

  13. Change From Baseline in Diastolic Blood Pressure

    Time frame: Baseline to Week 24

  14. Change From Baseline in Serum Uric Acid

    Time frame: Baseline to Week 24

  15. Change From Baseline in N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP)

    Time frame: Baseline to Week 24

Other outcomes

  1. Participants With Serious Adverse Events

    Number and percentage of participants with adverse events occurring during the treatment period.

    Time frame: From first dose through 30 days after the last dose

  2. Participants With Treatment-emergent Adverse Events

    Number and percentage of participants with serious adverse events.

    Time frame: From first dose through Week 24

  3. Participants With Hyperkalemia

    Number and percentage of participants with serum potassium \>5.5 mmol/L.

    Time frame: From first dose through Week 24

  4. Participants With Severe Hyperkalemia

    Number and percentage of participants with serum potassium \>6.0 mmol/L.

    Time frame: From first dose through Week 24

  5. Participants With Early eGFR Decline

    Number and percentage of participants with an eGFR decrease of at least 30% from baseline at Week 4.

    Time frame: Baseline to Week 4

  6. Change From Baseline in Serum Potassium

    Change in serum potassium from baseline.

    Time frame: Baseline to Week 24

  7. Change From Baseline in Homeostasis Model Assessment 2 of Insulin Resistance (HOMA2-IR)

    Change in HOMA2-IR from baseline.

    Time frame: Baseline to Week 24

  8. Change From Baseline in Fibrosis-4 Index (FIB-4)

    FIB-4 will be calculated using age, AST, platelet count, and ALT according to the protocol formula.

    Time frame: Baseline to Week 24

  9. Change From Baseline in Liver Stiffness Measurement

    Change in liver stiffness assessed by transient elastography (FibroScan)

    Time frame: Baseline to Week 24

  10. Participants With New-onset Diabetes

    Number and percentage of participants diagnosed with diabetes during the study according to applicable diagnostic guidelines.

    Time frame: Baseline through Week 28

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided — Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Feb 2027, 5 months later.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 5 months is below that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2026
First posted
Sep 30, 2026
StartEst.
Sep 2026
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07849348
Collaborators
Daqing Oil Field Hospital, First Affiliated Hospital Xi'an Jiaotong University, The Second Affiliated Hospital of Qiqihar Medical University, Capital Medical University, Huai'an Fifth People's Hospital, Heilongjiang Provicial Hospital, The First Affiliated Hospital of Henan University of Science and Technology, Shenzhen University General Hospital, Qiqihar First People's Hospital, Zibo Central Hospital, Hebei General Hospital, Suzhou Municipal Hospital, Yan'an University Affiliated Hospital, Tianjin People's Hospital, The First Hospital of Hebei Medical University, Daqing Longnan Hospital, Bayer Healthcare Co., Ltd., Luoyang First People's Hospital, Beijing Pinggu District Hospital
Responsible party
Linong Ji (Professor, Peking University People's Hospital) — Principal investigator
First posted
Sep 30, 2026
Start date
Sep 2026 (estimated)
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Sep 30, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Finerenone

Start the discussion